•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH
Top Cancer Stocks to Supercharge Your 2025 Portfolio
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
Novartis (NVS) Could Be a Great Choice
2 Dividend Growth Stocks to Buy and Hold Forever
Novartis' Pluvicto shown to slow prostate cancer in earlier setting
Novartis's Cancer Treatment Pluvicto Shows Positive Results in Trial
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Buy These 5 Low-Leverage Stocks Amid Volatile Market Sentiment
Novartis announces commencement of tender offer to acquire Regulus Therapeutics
Are You Looking for a High-Growth Dividend Stock?
If I Could Only Buy 2 Dividend Stocks Right Now (May 2025 Edition)
Here's Why Novartis (NVS) is a Strong Value Stock
Novartis (NVS) Upgraded to Buy: What Does It Mean for the Stock?
Should Value Investors Buy Novartis (NVS) Stock?
New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
Novartis to keep making malaria drugs if orders dry up amid aid cuts
Here's Why Novartis (NVS) is a Strong Momentum Stock
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.